Clinical Trial Update: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial update for dose-adjusted EPOCH-Rrituximab in adults with untreated Burkitt lymphoma and c-MYC positive diffuse large B-cell lymphoma; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Plasmablastic Lymphoma

Drugs mentioned

• EPOCH-Rrituximab (dose-adjusted EPOCH-Rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive | Phase 2 | Status: COMPLETED | Results posted: 2021-10-19